AMO959

DRUG2 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based ChemotherapyPSMA-positive mCRPC with prior exposure to at least one prior ARPI

Phase 1

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

RecruitingNCT07226986

Novartis PharmaceuticalsPSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

Start: 2025-12-05End: 2029-09-13Target: 123Updated: 2026-04-01

A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)

Not yet recruitingCTIS2025-521859-23-00

Novartis Pharma AGPSMA-positive mCRPC with prior exposure to at least one prior ARPI

Target: 61Updated: 2026-03-06